Paradigm Biocapital Advisors LP Arvinas, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Arvinas, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,339,961 shares of ARVN stock, worth $56.6 Million. This represents 2.08% of its overall portfolio holdings.
Number of Shares
2,339,961
Previous 2,438,149
4.03%
Holding current value
$56.6 Million
Previous $64.9 Million
11.2%
% of portfolio
2.08%
Previous 2.63%
Shares
9 transactions
Others Institutions Holding ARVN
# of Institutions
229Shares Held
68.4MCall Options Held
226KPut Options Held
285K-
Vanguard Group Inc Valley Forge, PA7.01MShares$169 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$163 Million7.19% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$151 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.85MShares$93.2 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.78MShares$67.3 Million1.09% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $1.29B
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...